Pralsetinib is under clinical development by Blueprint Medicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pralsetinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Pralsetinib in Solid Tumor

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pralsetinib overview

Pralsetinib (Gavreto) is an anticancer agent. It is formulated as hard gelatin capsules for oral route of administration. Gavreto is indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Gavreto is also indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy and RETfusion-positive medullary thyroid cancer (MTC) who require systemic therapy and who are radioactive iodine-refractory. Gavreto is indicated for the treatment of advanced or metastatic RET fusion-positive thyroid cancer (TC) who requires systemic therapy and radioactive iodine-refractory (if radioactive iodine treatment is appropriate) in adult and pediatric patients 12 years of age and older and RET-mutant medullary thyroid cancer (MTC) who requires systemic therapy, and adult and pediatric patients 12 years of age and older.
Pralsetinib (BLU-667) is under development for the treatment of solid tumors including medullary thyroid cancer, non-small cell lung cancer. It was also under development for the treatment of pancreatic, bile duct cancer (cholangiocarcinoma), colon, mesenchymal, salivary gland cancer and thymoma. It is administered orally in the form of capsule. BLU-667 acts by targeting RET receptor tyrosine kinase.

See Also:

Blueprint Medicines overview

Blueprint Medicines is a precision therapy company that invented medicines for the treatment of cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) for non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. Blueprint Medicines also offers GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. The company is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors and avapritinib to treat advanced systemic mastocytosis. The company utilizes its discovery which combines bioinformatics and drug design capabilities to develop its medicines. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Pralsetinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.